Oesophageal cancer

Why we focus on oesophageal cancer

There are around 9,000 new oesophageal cancer cases in the UK each year. Patients with oesophageal cancer have a poor survival rate (15% of patients survive for 5 years or more). There are two major reasons for such a poor prognosis; firstly, oesophageal cancers present at an advanced stage, and secondly, we do not fully understand the evolution of common precursor conditions such as Barrett’s oesophagus.

Barrett’s is the erosive replacement of the normal squamous epithelium with a metaplastic columnar phenotype and confers a 40-fold increase in oesophageal cancer risk over the normal population. The cancer risk for an individual Barrett’s patient is low but all patients are enrolled in regular and life-long endoscopic surveillance programmes in which there are no predictive biomarkers to evaluate an individual’s risk of developing cancer. When we consider that there are large numbers of Barrett’s patients, predicting an individual’s risk of developing cancer becomes critical.

What we do
  • Determine how clones expand within Barrett’s lesions.
  • Investigate the clonal evolution of Barrett’s glands in the progression to cancer.
  • Evaluate patterns of genetic and phenotypic diversity in Barrett’s glands as a means to determine cancer risk in patients.
  • We are affiliated with Prof David Kelsell, Centre for Cell Biology and Cutaneous Research, Blizard Institute who studies the development of dysplasia in oesophageal cancer.
Major Funders
  • Cancer Research UK
  • CORE
  • Barts Charity
  • Medical Research Council
Key Publications
Upcoming Events
  1. Thursday Seminar Series – Dr. Vivian Li

    June 20 @ 12:30 pm - 1:30 pm
  2. Distinguished Guest Lecture – Professor Robert Bristow

    June 20 @ 4:00 pm - 5:00 pm
© 2013 ~ 2019 Cancer Research UK Barts Centre